Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of digital therapeutic sinCephalea for personalised nutrition versus control for migraine prevention: A 12-week open-label randomised clinical trial.

Cephalalgia : an international journal of headache·2026
Same author

Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>.

Oncology letters·2026
Same author

Extended multisystem manifestations of hereditary α-tryptasemia in an allergy center cohort.

The journal of allergy and clinical immunology. Global·2026
Same author

Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeability.

The British journal of dermatology·2026
Same author

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

Acta dermato-venereologica·2026
Same author

HCA2 Receptors in Lymphocytes and Keratinocytes Affect Murine Contact Allergic Inflammation.

Experimental dermatology·2026
Same journal

The Impact of Chronic Spontaneous Urticaria on Sleep-A Systematic Review.

Dermatology and therapy·2026
Same journal

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy.

Dermatology and therapy·2026
Same journal

Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis.

Dermatology and therapy·2026
Same journal

Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis".

Dermatology and therapy·2026
Same journal

Correction: Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity in Adults in Taiwan: A Cross-sectional Survey.

Dermatology and therapy·2026
Same journal

A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'".

Dermatology and therapy·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Flat Mount Imaging of Mouse Skin and Its Application to the Analysis of Hair Follicle Patterning and Sensory Axon Morphology
13:58

Flat Mount Imaging of Mouse Skin and Its Application to the Analysis of Hair Follicle Patterning and Sensory Axon Morphology

Published on: June 25, 2014

21.4K

Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.

Henner Zirpel1, Linh Ha-Wissel1,2, Sarah Hobelsberger3

  • 1Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.

Dermatology and Therapy
|January 23, 2026
PubMed
Summary
This summary is machine-generated.

Risankizumab significantly improved psoriasis symptoms and reduced subclinical inflammation over 52 weeks. Optical coherence tomography (OCT) revealed lasting vascular changes, demonstrating its value in assessing treatment response.

Keywords:
Interleukin-23Optical coherence tomographyPsoriasisRisankizumab

More Related Videos

Fragility Assessment of Bovine Cortical Bone Using Scratch Tests
08:36

Fragility Assessment of Bovine Cortical Bone Using Scratch Tests

Published on: November 30, 2017

9.0K
Scanning Electron Microscopic Evaluation of Surface Defects of Remover Retreatment File After Single and Multiple Uses
03:07

Scanning Electron Microscopic Evaluation of Surface Defects of Remover Retreatment File After Single and Multiple Uses

Published on: October 11, 2024

1.1K

Related Experiment Videos

Last Updated: May 6, 2026

Flat Mount Imaging of Mouse Skin and Its Application to the Analysis of Hair Follicle Patterning and Sensory Axon Morphology
13:58

Flat Mount Imaging of Mouse Skin and Its Application to the Analysis of Hair Follicle Patterning and Sensory Axon Morphology

Published on: June 25, 2014

21.4K
Fragility Assessment of Bovine Cortical Bone Using Scratch Tests
08:36

Fragility Assessment of Bovine Cortical Bone Using Scratch Tests

Published on: November 30, 2017

9.0K
Scanning Electron Microscopic Evaluation of Surface Defects of Remover Retreatment File After Single and Multiple Uses
03:07

Scanning Electron Microscopic Evaluation of Surface Defects of Remover Retreatment File After Single and Multiple Uses

Published on: October 11, 2024

1.1K

Area of Science:

  • Dermatology
  • Immunology
  • Medical Imaging

Background:

  • Psoriasis is a chronic inflammatory skin disease impacting quality of life.
  • Risankizumab, an IL-23 inhibitor, effectively treats moderate-to-severe psoriasis.
  • Conventional assessments may not fully capture subclinical inflammation.

Purpose of the Study:

  • To evaluate the long-term efficacy of risankizumab in moderate-to-severe psoriasis.
  • To assess subclinical inflammation using optical coherence tomography (OCT).
  • To correlate clinical outcomes with OCT-derived structural and vascular changes.

Main Methods:

  • Prospective, single-center study of 22 moderate-to-severe psoriasis patients treated with risankizumab.
  • Clinical assessments (PASI, IGA, BSA) recorded over 52 weeks.
  • OCT imaging analyzed epidermal thickness and vascularity in lesional and perilesional skin.

Main Results:

  • Significant improvements in PASI and BSA scores by week 16 (p<0.001).
  • High rates of PASI 75/90/100 and IGA 0/1 achieved by week 52.
  • OCT demonstrated reductions in epidermal thickness and vascular parameters, including in perilesional skin.

Conclusions:

  • Risankizumab provides sustained clinical improvement and reduces subclinical inflammation in psoriasis.
  • OCT is a valuable tool for assessing deep vascular treatment responses.
  • Long-term risankizumab therapy offers benefits beyond visible skin clearance.